

BY E-MAIL AND CONFIRMATORY COPY BY HAND DELIVERY

3rd April, 2017

The Secretary
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,

Re: Declaration under Regulation 30 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith our annual disclosure under Regulation 30(3) of the said Regulation in respect of shareholding held by us in Krebs Biochemicals and Industries Limited as Promoters/PAC for the financial year of the Company ended 31st March, 2017.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully

For and on Ipca Laboratories Limited




Harish P. Kamath
Company Secretary

Encl: a/a

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051

Krebs Biochemicals & Industries Ltd.
Plot No 34, 8-2-577/B, Maas Heights,
3rd Floor, Road No 8,
Banjara Hills, Hyderabad 500 034

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Format for disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Part A- Details of shareholding

1. Name of the Target Company	Krebs Biochemicals & Industries Limited		
2. Names of the Stock Exchanges where the shares of the TC are listed	1. BSE Limited 2. National Stock Exchange of India Limited		
3. Particulars of the shareholder(s): a. Name of the person(s) together with Persons Acting in Concert (PAC) whose total (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b. Name(s) of the promoter(s), member of the promoter group and PAC with him	Ipca Laboratories Limited		
4. Particulars of the shareholding of the person(s) mentioned at (3) above	Number of shares	% w.r.t total share/voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on 31 st March, 2017 , holding of			
a) Shares	41,00,100	29.83%	29.83%
b) Voting rights (otherwise than by shares)	Nil	0.00%	0.00%
c) Warrants	Nil	0.00%	0.00%
d) Convertible Securities	Nil	0.00%	0.00%
e) Any other instrument that would entitle the holder to receive shares in the TC.	Nil	0.00%	0.00%
Total	41,00,100	29.83%	29.83%



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613


E: ipca@ipca.com CIN: L24239MH1949PLC007837

Signature of the Authorised Signatory

Place:

Date: 3rd April, 2017

FOR IPCA LABORATORIES LIMITED



HARISH P. KAMATH
COMPANY SECRETARY

Note: In case of Promoter(s) making disclosure under Regulation 30(2), no additional disclosure under Regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 | F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 | F: +91 22 2868 6613

E: ipca@ipca.com | CIN: L24239MH1949PLC007837